## FORMULA (I)

· 2HCI · H<sub>2</sub>O




FIG. 2




FIG. 3A





FIG. 3B



**FIG. 4A** 






FIG. 4B



Percent Relaxation from 10 μM Phenylephrine

FIG. 5








FIG. 6



Percent Inhibition Following Treatment with Y-27632 (% of control response to PE)

IG. 7A


Appln. Ser. To Be Assigned Treatment of Erectile Dysfunction Inventors: MILLS et al. Express Mail No. EL 894 955 880 US



Percent Inhibition Following Treatment with Y-27632 (% of control response to PE)

FIG. 7B





Percent Maximum Relaxation Following Contraction to 10 µM PE




FIG. 8





FIG. 9









FIG. 10B

2 DOCA sham 2 0.8 9.0 0 ICP/MAP Following Treatment with Y-27632 (50nmol)





**FIG. 11A** 



**FIG. 11B**